189 related articles for article (PubMed ID: 16426720)
1. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine.
Gama CS; Salvador M; Andreazza AC; Kapczinski F; Silva Belmonte-de-Abreu P
Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):512-5. PubMed ID: 16426720
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia.
Kunz M; Gama CS; Andreazza AC; Salvador M; Ceresér KM; Gomes FA; Belmonte-de-Abreu PS; Berk M; Kapczinski F
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Oct; 32(7):1677-81. PubMed ID: 18657586
[TBL] [Abstract][Full Text] [Related]
3. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings.
Ben Othmen L; Mechri A; Fendri C; Bost M; Chazot G; Gaha L; Kerkeni A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):155-9. PubMed ID: 17804133
[TBL] [Abstract][Full Text] [Related]
4. Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients: effects of antipsychotic drugs.
Huang TL; Liou CW; Lin TK
Psychiatry Res; 2010 May; 177(1-2):18-21. PubMed ID: 20381168
[TBL] [Abstract][Full Text] [Related]
5. The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia.
Zhou D; Zhang X; Su J; Nan Z; Cui Y; Liu J; Guan Z; Zhang P; Shen Y
Chin Med J (Engl); 1999 Dec; 112(12):1093-6. PubMed ID: 11721446
[TBL] [Abstract][Full Text] [Related]
6. Decreased serum neurotrophin 3 in chronically medicated schizophrenic males.
Vargas HE; Gama CS; Andreazza AC; Medeiros D; Stertz L; Fries G; Palha J; Cereser KM; Berk M; Kapczinski F; Belmonte-de-Abreu PS
Neurosci Lett; 2008 Aug; 440(3):197-201. PubMed ID: 18572319
[TBL] [Abstract][Full Text] [Related]
7. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
8. Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients.
Miljevic C; Nikolic M; Nikolic-Kokic A; Jones DR; Niketic V; Lecic-Tosevski D; Spasic MB
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):303-7. PubMed ID: 19962416
[TBL] [Abstract][Full Text] [Related]
9. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics.
Zhang XY; Tan YL; Cao LY; Wu GY; Xu Q; Shen Y; Zhou DF
Schizophr Res; 2006 Jan; 81(2-3):291-300. PubMed ID: 16309894
[TBL] [Abstract][Full Text] [Related]
10. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients.
Raffa M; Mechri A; Othman LB; Fendri C; Gaha L; Kerkeni A
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1178-83. PubMed ID: 19576938
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress in blood platelets from schizophrenic patients.
Dietrich-Muszalska A; Olas B; Rabe-Jablonska J
Platelets; 2005 Nov; 16(7):386-91. PubMed ID: 16236599
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males.
Gama CS; Salvador M; Andreazza AC; Lobato MI; Berk M; Kapczinski F; Belmonte-de-Abreu PS
Neurosci Lett; 2008 Mar; 433(3):270-3. PubMed ID: 18255229
[TBL] [Abstract][Full Text] [Related]
13. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
[TBL] [Abstract][Full Text] [Related]
14. Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia.
Vidović B; Milovanović S; Dorđević B; Kotur-Stevuljević J; Stefanović A; Ivanišević J; Miljković M; Spasić S; Stojanović D; Pantović M
Psychiatr Danub; 2014 Sep; 26(3):205-13. PubMed ID: 25191766
[TBL] [Abstract][Full Text] [Related]
15. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics.
Grillo RW; Ottoni GL; Leke R; Souza DO; Portela LV; Lara DR
J Psychiatr Res; 2007; 41(1-2):31-5. PubMed ID: 16546213
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation.
Gama CS; Berk M; Andreazza AC; Kapczinski F; Belmonte-de-Abreu P
Braz J Psychiatry; 2008 Dec; 30(4):337-40. PubMed ID: 19142408
[TBL] [Abstract][Full Text] [Related]
17. Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs.
Tsai MC; Liou CW; Lin TK; Lin IM; Huang TL
Psychiatry Res; 2013 Oct; 209(3):284-90. PubMed ID: 23497820
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients.
Casademont J; Garrabou G; Miró O; López S; Pons A; Bernardo M; Cardellach F
J Clin Psychopharmacol; 2007 Jun; 27(3):284-8. PubMed ID: 17502776
[TBL] [Abstract][Full Text] [Related]
19. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia.
Akyol O; Yanik M; Elyas H; Namli M; Canatan H; Akin H; Yuce H; Yilmaz HR; Tutkun H; Sogut S; Herken H; Ozyurt H; Savas HA; Zoroglu SS
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):123-31. PubMed ID: 15610954
[TBL] [Abstract][Full Text] [Related]
20. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report.
Frey BN; Andreazza AC; Kunz M; Gomes FA; Quevedo J; Salvador M; Gonçalves CA; Kapczinski F
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):283-5. PubMed ID: 16859818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
